C J Ferro

Summary

Affiliation: University Hospital Birmingham
Country: UK

Publications

  1. pmc Benefits of Aldosterone Receptor Antagonism in Chronic Kidney Disease (BARACK D) trial-a multi-centre, prospective, randomised, open, blinded end-point, 36-month study of 2,616 patients within primary care with stage 3b chronic kidney disease to compare t
    Nathan R Hill
    Nuffield Department of Primary Care Health Sciences, University of Oxford, Radcliffe Observatory Quarter, Woodstock Road, Oxford OX2 6GG, UK
    Trials 15:160. 2014
  2. pmc Optimising the accuracy of blood pressure monitoring in chronic kidney disease: the utility of BpTRU
    Shona Brothwell
    Department of Renal Medicine, Queen Elizabeth Hospital, University Hospitals Birmingham, Birmingham, United Kingdom
    BMC Nephrol 14:218. 2013
  3. pmc Spironolactone to prevent cardiovascular events in early-stage chronic kidney disease (STOP-CKD): study protocol for a randomized controlled pilot trial
    Khai P Ng
    Department of Renal Medicine, Queen Elizabeth Hospital Birmingham, Mindelsohn Way, Birmingham B15 2WB, UK
    Trials 15:158. 2014
  4. pmc Cytomegalovirus seropositivity is associated with increased arterial stiffness in patients with chronic kidney disease
    Nadezhda A Wall
    School of Immunity and Infection, University of Birmingham, Birmingham, United Kingdom
    PLoS ONE 8:e55686. 2013
  5. pmc Aortic calcification and femoral bone density are independently associated with left ventricular mass in patients with chronic kidney disease
    Colin D Chue
    School of Clinical and Experimental Medicine, College of Medical and Dental Sciences, University of Birmingham, Birmingham, United Kingdom
    PLoS ONE 7:e39241. 2012
  6. pmc The natural history of, and risk factors for, progressive chronic kidney disease (CKD): the Renal Impairment in Secondary care (RIISC) study; rationale and protocol
    Stephanie Stringer
    Department of Nephrology, University Hospital Birmingham, Birmingham B15 2WB, UK
    BMC Nephrol 14:95. 2013
  7. pmc Cardiovascular effects of sevelamer in stage 3 CKD
    Colin D Chue
    Schools of Clinical and Experimental Medicine, University of Birmingham, Birmingham, United Kingdom
    J Am Soc Nephrol 24:842-52. 2013
  8. pmc Evaluating the effects of sevelamer carbonate on cardiovascular structure and function in chronic renal impairment in Birmingham: the CRIB-PHOS randomised controlled trial
    Colin D Chue
    Department of Nephrology, Queen Elizabeth Hospital and University of Birmingham, Birmingham, UK
    Trials 12:30. 2011
  9. ncbi request reprint Does immunosuppressant medication lower blood pressure and arterial stiffness in patients with chronic kidney disease? An observational study
    Charles J Ferro
    Department of Nephrology, University of Birmingham and University Hospital Birmingham, Birmingham, UK
    Hypertens Res 34:113-9. 2011
  10. ncbi request reprint Serum phosphate is associated with left ventricular mass in patients with chronic kidney disease: a cardiac magnetic resonance study
    Colin D Chue
    Department of Cardiology, University Hospitals Birmingham NHS Foundation Trust, UK
    Heart 98:219-24. 2012

Collaborators

Detail Information

Publications16

  1. pmc Benefits of Aldosterone Receptor Antagonism in Chronic Kidney Disease (BARACK D) trial-a multi-centre, prospective, randomised, open, blinded end-point, 36-month study of 2,616 patients within primary care with stage 3b chronic kidney disease to compare t
    Nathan R Hill
    Nuffield Department of Primary Care Health Sciences, University of Oxford, Radcliffe Observatory Quarter, Woodstock Road, Oxford OX2 6GG, UK
    Trials 15:160. 2014
    ..The use of ARA in CKD has therefore been increasingly advocated. However, no large study of ARA with renal or CVD outcomes is underway...
  2. pmc Optimising the accuracy of blood pressure monitoring in chronic kidney disease: the utility of BpTRU
    Shona Brothwell
    Department of Renal Medicine, Queen Elizabeth Hospital, University Hospitals Birmingham, Birmingham, United Kingdom
    BMC Nephrol 14:218. 2013
    ..The aim of this study was to evaluate a fully automated sphygmomanometer for optimising the accuracy of blood pressure measurements in the setting of secondary care renal clinics...
  3. pmc Spironolactone to prevent cardiovascular events in early-stage chronic kidney disease (STOP-CKD): study protocol for a randomized controlled pilot trial
    Khai P Ng
    Department of Renal Medicine, Queen Elizabeth Hospital Birmingham, Mindelsohn Way, Birmingham B15 2WB, UK
    Trials 15:158. 2014
    ..The aim of this study is to determine whether low-dose spironolactone can safely lower arterial stiffness in patients with stage 3 chronic kidney disease in the primary care setting...
  4. pmc Cytomegalovirus seropositivity is associated with increased arterial stiffness in patients with chronic kidney disease
    Nadezhda A Wall
    School of Immunity and Infection, University of Birmingham, Birmingham, United Kingdom
    PLoS ONE 8:e55686. 2013
    ..We examined whether CMV seropositivity was associated with increased arterial stiffness in patients with chronic kidney disease...
  5. pmc Aortic calcification and femoral bone density are independently associated with left ventricular mass in patients with chronic kidney disease
    Colin D Chue
    School of Clinical and Experimental Medicine, College of Medical and Dental Sciences, University of Birmingham, Birmingham, United Kingdom
    PLoS ONE 7:e39241. 2012
    ..The mechanism is unknown. We assessed the relationship between vascular calcification, femoral bone density and left ventricular mass in patients with stage 3 non-diabetic chronic kidney disease in a cross-sectional observational study...
  6. pmc The natural history of, and risk factors for, progressive chronic kidney disease (CKD): the Renal Impairment in Secondary care (RIISC) study; rationale and protocol
    Stephanie Stringer
    Department of Nephrology, University Hospital Birmingham, Birmingham B15 2WB, UK
    BMC Nephrol 14:95. 2013
    ..Accurate mapping of the bio-clinical determinants of this group will enable improved risk stratification and direct the development of better targeted management for people with CKD...
  7. pmc Cardiovascular effects of sevelamer in stage 3 CKD
    Colin D Chue
    Schools of Clinical and Experimental Medicine, University of Birmingham, Birmingham, United Kingdom
    J Am Soc Nephrol 24:842-52. 2013
    ..In conclusion, this study does not provide evidence that sevelamer carbonate improves LV mass, LV function, or arterial stiffness in stage 3 nondiabetic CKD...
  8. pmc Evaluating the effects of sevelamer carbonate on cardiovascular structure and function in chronic renal impairment in Birmingham: the CRIB-PHOS randomised controlled trial
    Colin D Chue
    Department of Nephrology, Queen Elizabeth Hospital and University of Birmingham, Birmingham, UK
    Trials 12:30. 2011
    ..There is accumulating evidence that phosphate promotes arterial stiffening through structural vascular alterations such as medial calcification, which are already apparent in the early stages of chronic kidney disease...
  9. ncbi request reprint Does immunosuppressant medication lower blood pressure and arterial stiffness in patients with chronic kidney disease? An observational study
    Charles J Ferro
    Department of Nephrology, University of Birmingham and University Hospital Birmingham, Birmingham, UK
    Hypertens Res 34:113-9. 2011
    ..5 ± 1.8 vs. 8.8 ± 1.9 m s(-1); P = 0.02). This study suggests that immunosuppression might be a method of reducing blood pressure and arterial stiffness in patients with chronic kidney disease...
  10. ncbi request reprint Serum phosphate is associated with left ventricular mass in patients with chronic kidney disease: a cardiac magnetic resonance study
    Colin D Chue
    Department of Cardiology, University Hospitals Birmingham NHS Foundation Trust, UK
    Heart 98:219-24. 2012
    ..To explore the relationship between serum phosphate, arterial stiffness and left ventricular mass (LVM) in patients with early-stage chronic kidney disease (CKD)...
  11. ncbi request reprint Is lowering phosphate exposure the key to preventing arterial stiffening with age?
    C J Ferro
    Department of Nephrology, Queen Elizabeth Hospital, University Hospital Birmingham NHS Foundation Trust, Edgbaston, Birmingham, West Midlands B15 2TH, UK
    Heart 95:1770-2. 2009
    ..It is hypothesised that reducing phosphate intake will attenuate the progression of arterial stiffness with major beneficial effects upon cardiovascular mortality and morbidity...
  12. ncbi request reprint Understanding the effects of chronic kidney disease on cardiovascular risk: are there lessons to be learnt from healthy kidney donors?
    W E Moody
    Department of Cardiovascular Medicine, Queen Elizabeth Hospital, University of Birmingham, Birmingham, UK
    J Hum Hypertens 26:141-8. 2012
    ....
  13. ncbi request reprint Central pulse pressure in patients with chronic kidney disease and in renal transplant recipients
    K P Ng
    Department of Nephrology, Queen Elizabeth Hospital Birmingham, Birmingham, UK
    J Hum Hypertens 28:180-5. 2014
    ..This study demonstrates that in these patients most of the variability in cPP can be explained by pPP. Additionally, cPP does not appear to provide additional information beyond pPP in determining PWV and LVMI. ..
  14. ncbi request reprint Aortic distensibility and arterial-ventricular coupling in early chronic kidney disease: a pattern resembling heart failure with preserved ejection fraction
    N C Edwards
    Department of Cardiology, University of Birmingham and University Hospital Birmingham, Birmingham, UK
    Heart 94:1038-43. 2008
    ..To examine arterial and left ventricular function and their interaction in patients with early-stage chronic kidney disease (CKD)...
  15. ncbi request reprint The treatment of coronary artery disease in patients with chronic kidney disease
    N C Edwards
    Research Fellow in Cardiology, Department of Cardiovascular Medicine, University of Birmingham, Birmingham, UK
    QJM 99:723-36. 2006
    ..The high rate of late adverse cardiovascular events after both CABG and angioplasty accentuates the need for effective secondary preventive therapy disease in these high-risk patients...
  16. ncbi request reprint Serum phosphate but not pulse wave velocity predicts decline in renal function in patients with early chronic kidney disease
    Colin D Chue
    Department of Cardiology, Queen Elizabeth Hospital, Birmingham and University of Birmingham, Birmingham, UK
    Nephrol Dial Transplant 26:2576-82. 2011
    ..We sought to determine whether serum phosphate and markers of arterial stiffness predict progression of renal dysfunction in patients with early CKD...